Rafarma Pharmaceuticals, Inc.
RAFA
Rank in Stocks
#32507
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that... Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Share Price
$0.0173
Last synced: 2026-11-09
Market Cap
$1.52M
Change (1 day)
50.43%
Change (1 year)
-50.57%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Rafarma Pharmaceuticals, Inc. (RAFA)
Category
Healthcare
Operating Margin for Rafarma Pharmaceuticals, Inc. (RAFA)
Operating Margin as of November 2026 TTM: 5.50%
According to Rafarma Pharmaceuticals, Inc.'s latest financial reports, its current operating margin (TTM) is 5.50%. At the end of 2025 the company had an operating margin of 5.33%.
Operating Margin history for Rafarma Pharmaceuticals, Inc. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 5.50% | 3.19% |
| 2025 | 5.33% | 19.51% |
| 2024 | 4.46% | 44.34% |
| 2023 | 3.09% | -72.21% |
| 2022 | 11.12% | -41.54% |
| 2021 | 19.02% | -25.50% |
| 2020 | 25.53% | -773.61% |
| 2019 | -3.79% | -95.12% |
| 2018 | -77.60% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -96.47% |
DE
|
|
| 19.68% | -96.42% |
DE
|
|
| 13.26% | -97.59% |
JP
|
|
| 17.08% | -96.89% |
CH
|
|
| 14.92% | -97.29% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Rafarma Pharmaceuticals, Inc.'s operating margin
What is Rafarma Pharmaceuticals, Inc.'s operating margin?
Rafarma Pharmaceuticals, Inc.'s operating margin is 5.50%, as of Nov 2026.
What was Rafarma Pharmaceuticals, Inc.'s operating margin in 2025?
In 2025, Rafarma Pharmaceuticals, Inc.'s operating margin was 5.33%, compared with 4.46% in 2024.
How has Rafarma Pharmaceuticals, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Rafarma Pharmaceuticals, Inc.'s operating margin was highest in 2020 (25.53%) and lowest in 2023 (3.09%).
How does Rafarma Pharmaceuticals, Inc.'s operating margin compare with similar companies?
Rafarma Pharmaceuticals, Inc.'s operating margin (5.50%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.